NCT06479954View on ClinicalTrials.gov

Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use.

Active, not recruitingOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

February 25, 2027

Study Completion Date

February 25, 2027

Conditions
Relapsed and Refractory Multiple Myeloma (RRMM)
Trial Locations (1)

Unknown

Pfizer, Tokyo

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06479954 - Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use. | Biotech Hunter | Biotech Hunter